We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 21, 2020

BL-8040 CXCR4 Antagonist Is Safe and Demonstrates Antileukemic Activity in Combination With Cytarabine for Relapsed/Refractory AML

Cancer

 

Additional Info

Cancer
BL-8040 CXCR4 Antagonist Is Safe and Demonstrates Antileukemic Activity in Combination With Cytarabine for the Treatment of Relapsed/Refractory Acute Myelogenous Leukemia: An Open-Label Safety and Efficacy Phase 2a Study
Cancer 2020 Dec 03;[EPub Ahead of Print], G Borthakur, Y Ofran, MS Tallman, J Foran, GL Uy, JF DiPersio, MM Showel, A Shimoni, A Nagler, JM Rowe, JK Altman, M Abraham, A Peled, S Shaw, O Bohana-Kashtan, E Sorani, Y Pereg, A Foley-Comer, G Oberkovitz, TM Lustig, I Glicko-Kabir, A Aharon, A Vainstein-Haras, SE Kadosh, E Samara, AN Al-Rawi, N Pemmaraju, C Bueso-Ramos, JE Cortes, M Andreeff

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading